You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
仟源醫藥(300254.SZ):子公司獲得藥品註冊證書及化學原料藥上市申請批准通知書
格隆匯 12-03 17:00

格隆匯12月3日丨仟源醫藥(300254.SZ)公佈,近日,山西仟源醫藥集團股份有限公司的子公司杭州仟源保靈藥業有限公司收到國家藥品監督管理局簽發的“精氨酸培哚普利片(5mg、10mg)”《藥品註冊證書》,子公司江蘇嘉逸醫藥有限公司收到國家藥品監督管理局簽發的精氨酸培哚普利《化學原料藥上市申請批准通知書》。

精氨酸培哚普利片適用於高血壓與充血性心力衰竭的治療,培哚普利是一種血管緊張素轉換酶抑制劑,血管緊張素轉換酶能使血管緊張素Ⅰ轉化成有收縮血管作用的血管緊張素Ⅱ。此外,該酶能刺激腎皮質分泌醛固酮,還能使具有舒張血管功能的緩激肽降解為無活性的七肽,培哚普利通過它的活性代謝物培哚普利拉抑制血管緊張素轉換酶而發揮降血壓作用。

精氨酸培哚普利片原研為法國施維雅,公司精氨酸培哚普利片是國內首仿獲得《藥品註冊證書》,並視同通過一致性評價,該品種已進入國家醫保目錄乙類。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account